6.1.1.2. Intermediate- and long-acting insulins
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes. Restricted to use in accordance with local guidance which includes information on preferred alternative options.
Prescribing Notes:
Note: Insulin degludec is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.
Restrictions:
Insulin detemir (Levemir®) is restricted to use in children, adolescent and adult patients with severe/ frequent nocturnal hypoglycaemia. Not for routine use in type 2 diabetes unless patients suffers from recurrent episodes of hypoglycaemia. Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Restrictions:
Restricted to patients with type 1 diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.
Restricted to initiation by clinicians, either in primary care or the acute setting, experienced in the treatment of diabetes.
Prescribing Notes:
It is good practice to prescribe biosimilar insulins by brand name. The current preferred brand in NHSGGC is Semglee®
Please note: Insulin glargine is available in two strengths and caution should be taken in prescribing, dispensing and administration to ensure the correct strength is received.
Insulin glargine 300 units/ml (Toujeo®) is further restricted to use in patients where the use of high-strength insulin is appropriate.